Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
147.37
+5.39 (3.80%)
At close: Oct 14, 2026, 4:00 PM EDT
148.60
+1.23 (0.83%)
After-hours: Oct 14, 2026, 7:59 PM EDT
Merck & Co. Employees
Merck & Co. had 75,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Merck & Co. the 456th largest employer in the world and 123rd in the United States.
Employees
75,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$887,587
Profits / Employee
$42,307
Market Cap
363.59B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,000 | 0 | - |
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| AbbVie | 57,000 |
| Eli Lilly and Company | 50,000 |
MRK News
- 14 hours ago - Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make - CNBC
- 1 day ago - Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry - WSJ
- 1 day ago - FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban - Business Insider
- 1 day ago - ‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks - Market Watch
- 1 day ago - Merck announces Diaz to join Board of Directors - TheFly
- 1 day ago - Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors - Business Wire
- 1 day ago - Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026 - Business Wire
- 2 days ago - Merck price target lowered to $145 from $150 at RBC Capital - TheFly